In the last edition, I asked: what if we stopped waiting for infections to occur and instead focused on maintaining the ecological barriers that prevent them?
Some of you asked: "This sounds great, but what do I actually do differently in real life?"
Fair question. Let me show you.
You are already practicing microbiome medicine. You just haven't been framing it that way.
What You're Already Doing
Think about your last antimicrobial stewardship consult.
A patient is on piperacillin-tazobactam for pneumonia. Cultures grow Streptococcus pneumoniae susceptible to ceftriaxone. You recommend narrowing therapy.
Here's how we typically frame this decision:
"Narrow-spectrum is adequate for identified pathogen"
"Reduces selective pressure for resistance"
"Decreases unnecessary broad-spectrum exposure"
All true. But here's what's actually happening at a microbiome level:
Piperacillin-tazobactam decimates anaerobic bacteria, particularly Bacteroides species that provide colonization resistance against C. diff and other pathogens. It disrupts bile acid metabolism. It eliminates bacteria producing short-chain fatty acids that maintain gut barrier integrity.
Ceftriaxone has a narrower anaerobic spectrum. It still causes microbiome disruption, but significantly less.
That's preventive microbiome medicine.
You're already doing it.
You're just not talking about it this way.
This Is Microbiome Stewardship
Let me name and define this:
Microbiome Stewardship = Optimizing antimicrobial use to preserve colonization resistance, protect beneficial microbiota, and prevent infections through ecological maintenance.
It's not replacing antimicrobial stewardship.
It's making explicit what was always implicit. You've been doing it all along.
Now it has a name.
Reframing Changes Everything
Here's why how we frame it matters:
When stewardship is about "preventing resistance," the benefit feels abstract and population-level.
It's for future patients, future infections, the theoretical resistance problem.
That changes how we communicate with clinicians who push back on narrow-spectrum recommendations.
Compare these conversations:
Resistance frame:
Clinician: "The patient is doing well on pip-tazo. Why change?"
You: "To reduce selective pressure for resistance."
Clinician: "But they're stable. The resistance risk seems theoretical."
Microbiome frame:
Clinician: "The patient is doing well on pip-tazo. Why change?"
You: "Pip-tazo is messing up their gut microbiome and wiping out protective bacteria. This increases their risk for C. diff, secondary infections, and prolonged recovery. Ceftriaxone treats the pneumonia while preserving colonization resistance."
Clinician: "Oh, yeah. That makes sense. Let's switch."
Same recommendation. Different frame. Much more compelling.
What Changes in Practice
Once you start thinking about antimicrobial decisions through a microbiome lens, several things shift:
1. Duration matters differently
We already say "shortest effective duration." But the reason becomes more concrete:
Every extra day of broad-spectrum therapy causes cumulative microbiome damage that increases infection risk.
A patient on seven days of pip-tazo versus four days doesn't just face marginally higher resistance risk.
>>> They face measurably greater microbiome disruption, delayed microbiome recovery, and higher risk of C. diff and secondary infections.<<<<
2. Empiric choices matter more upfront
When choosing empiric therapy, we balance "adequate coverage" against "unnecessary spectrum."
Every hour of unnecessarily broad therapy causes microbiome damage that takes weeks to months to recover.
If you can start with ceftriaxone + azithromycin for community-acquired pneumonia instead of defaulting to pip-tazo, you've protected weeks of microbiome recovery time.
3. Post-treatment matters
Traditional stewardship stops when antibiotics stop.
Microbiome stewardship asks: what's the plan for microbiome recovery?
For most patients after short courses, natural recovery is adequate.
But for patients receiving prolonged or repeated broad-spectrum therapy, we should be thinking about:
Is microbiome recovery happening?
Are there strategies to support it?
What's the risk of recurrent infection due to persistent microbiome disruption?
The Practical Questions
I know what you're thinking and I get it:
"This sounds reasonable, but I don't have microbiome testing. How do I actually assess microbiome disruption or recovery?"
Fair point. Here's what you can do today without any special diagnostics:
Risk-stratify based on antimicrobial exposure:
Single short course of narrow-spectrum: low microbiome disruption, natural recovery expected
Prolonged broad-spectrum (>7-10 days): moderate disruption, slower recovery
Multiple courses or carbapenem/pip-tazo: high disruption, prolonged recovery, elevated infection risk
Use clinical proxies:
Development of C. diff during or after therapy: clear evidence of microbiome disruption and colonization resistance failure
Secondary infections: may reflect microbiome-mediated loss of colonization resistance
Delayed functional recovery: emerging evidence links microbiome disruption to prolonged recovery
Counsel patients explicitly:
"The antibiotics we're using will treat your infection, but they'll also disrupt your normal gut bacteria. That disruption can take weeks to months to fully recover and may increase your risk for infections like C. diff. Here's why we're choosing the narrowest-spectrum option that will work..."
This isn't just good medicine. It's informed consent about microbiome impact.
Where This Gets Interesting
Once we start framing stewardship as microbiome protection, new questions emerge:
Should we be more aggressive about stopping prophylaxis?
Many patients stay on antibiotics "just in case" long after indication has passed. The microbiome frame makes the cost of continuation more concrete.
Should we think differently about prophylaxis selection?
If a patient needs prolonged surgical prophylaxis, does the choice of agent matter for microbiome preservation? (Yes. Significantly.)
When should we consider probiotic or microbiome restoration strategies?
Current evidence for most probiotics is weak.
But for specific populations receiving prolonged broad-spectrum therapy, targeted strategies might prevent infections rather than just treating them after they occur.
These aren't questions with clear answers yet. But they're the right questions.
The Leadership Opportunity
Here's what you should consider:
Every stewardship intervention you make is a microbiome intervention.
Every time you narrow therapy, shorten duration, or optimize agent selection, you're practicing preventive microbiome medicine.
When we present stewardship metrics to hospital leadership, don't just show "days of therapy saved" or "cost reduction."
Show "patients protected from microbiome disruption" and "C. diff cases prevented through microbiome-preserving stewardship."
When we teach residents about narrow-spectrum therapy, don't just talk about resistance. Teach them about colonization resistance, microbiome recovery, and infection prevention through ecological maintenance.
Reframe what we already do as the preventive medicine it actually is.
What's Next
We've established that antimicrobial stewardship is microbiome stewardship - and you're already practicing it.
But here's where it gets more interesting:
What if we could actually see the microbiome impact we're talking about?
In the next edition, I'm diving into metagenomic next-generation sequencing (mNGS) and microbiome profiling - not as fancy diagnostic tools, but as windows into real-time colonization resistance.
If we can see comprehensive microbiome composition, can we predict infections before they occur? Can we identify patients who need intervention before their next CDI or UTI or bacteremia?
And if we can predict infections, can we prevent them?
That's the diagnostic revolution happening right now. And ID physicians should be leading it.
Now, It's Your Turn
Do you currently frame stewardship recommendations using microbiome language?
How do clinicians respond when you talk about microbiome preservation versus resistance prevention?
What would help you communicate microbiome impact more effectively in stewardship consults?
Let's talk strategy in the comments.